OBJECTIVES: To evaluate the relationship of a performance-based measure of visual functioning to clinical and subjective measures in glaucoma patients. DESIGN: Cross-sectional survey of glaucoma patients. PARTICIPANTS: Forty-three patients with primary open-angle glaucoma. METHODS: Patients were evaluated using a novel performance-based measure, the Assessment of Function Related to Vision (AFREV), standard clinical tests of visual function, and the National Eye Institute's Visual Functioning Questionnaire (NEI-VFQ-25), a self-reported quality of life measure. Correlations of the AFREV scores with visual field scores, monocular and binocular visual acuity, contrast sensitivity scores, and NEI-VFQ scores were calculated. Rasch analysis was used to estimate the visual ability required by each task of AFREV for a particular response (item measures) and to estimate the visual ability of each patient (person measures). MAIN OUTCOME MEASURES: AFREV and NEI-VFQ total scores. RESULTS: The AFREV total scores were highly correlated with contrast sensitivity (r = 0.772), binocular visual acuity (r = -0.768), better-eye visual acuity (r = -0.737), worse-eye visual acuity (r = -0.675), and Estermann visual field efficiency scores (r = 0.606) as well as with NEI-VFQ scores (r = 0.70). The resulting index, constructed from 5 items of the AFREV, is unidimensional, thereby satisfying the primary assumption of the Rasch model. The Rasch person-item map demonstrates that the "putting stick into holes" and "reading small print" tests require the most visual ability. CONCLUSIONS: The AFREV performance-based measure, a new test of a spectrum of activities, correlates well with some standard measures of visual function and certain aspects of self-report assessments. AFREV appears to be a valid measure of performance ability that may provide information not obtainable from standard measures of visual function or subjective surveys.
OBJECTIVES: To evaluate the relationship of a performance-based measure of visual functioning to clinical and subjective measures in glaucomapatients. DESIGN: Cross-sectional survey of glaucomapatients. PARTICIPANTS: Forty-three patients with primary open-angle glaucoma. METHODS:Patients were evaluated using a novel performance-based measure, the Assessment of Function Related to Vision (AFREV), standard clinical tests of visual function, and the National Eye Institute's Visual Functioning Questionnaire (NEI-VFQ-25), a self-reported quality of life measure. Correlations of the AFREV scores with visual field scores, monocular and binocular visual acuity, contrast sensitivity scores, and NEI-VFQ scores were calculated. Rasch analysis was used to estimate the visual ability required by each task of AFREV for a particular response (item measures) and to estimate the visual ability of each patient (person measures). MAIN OUTCOME MEASURES: AFREV and NEI-VFQ total scores. RESULTS: The AFREV total scores were highly correlated with contrast sensitivity (r = 0.772), binocular visual acuity (r = -0.768), better-eye visual acuity (r = -0.737), worse-eye visual acuity (r = -0.675), and Estermann visual field efficiency scores (r = 0.606) as well as with NEI-VFQ scores (r = 0.70). The resulting index, constructed from 5 items of the AFREV, is unidimensional, thereby satisfying the primary assumption of the Rasch model. The Rasch person-item map demonstrates that the "putting stick into holes" and "reading small print" tests require the most visual ability. CONCLUSIONS: The AFREV performance-based measure, a new test of a spectrum of activities, correlates well with some standard measures of visual function and certain aspects of self-report assessments. AFREV appears to be a valid measure of performance ability that may provide information not obtainable from standard measures of visual function or subjective surveys.
Authors: Mark J Atkinson; Steven Tally; Chris W Heichel; Igor Kozak; Jennifer Leich; Ashley Levack Journal: Qual Life Res Date: 2012-03-21 Impact factor: 4.147
Authors: Chelsea L Reighard; Manju R Pillai; Sujani Shroff; George L Spaeth; Stephen G Schilling; Sheryl S Wizov; Joshua D Stein; Alan L Robin; Vidya Raja; Joshua R Ehrlich Journal: Ophthalmol Glaucoma Date: 2019-06-18
Authors: David P Crabb; Nicholas D Smith; Franziska G Rauscher; Catharine M Chisholm; John L Barbur; David F Edgar; David F Garway-Heath Journal: PLoS One Date: 2010-03-16 Impact factor: 3.240
Authors: Pradeep Y Ramulu; Bonnielin K Swenor; Joan L Jefferys; David S Friedman; Gary S Rubin Journal: Invest Ophthalmol Vis Sci Date: 2013-01-23 Impact factor: 4.799
Authors: Angeline M Nguyen; Suzanne W van Landingham; Robert W Massof; Gary S Rubin; Pradeep Y Ramulu Journal: Invest Ophthalmol Vis Sci Date: 2014-07-22 Impact factor: 4.799